This paper provides a comprehensive overview of breast cancer, the most common cancer affecting women and a leading cause of cancer-related deaths. It examines the key risk factors and prognostic indicators that influence treatment outcomes, then surveys the major treatment modalities available to patients: surgical options ranging from lumpectomy to radical mastectomy and breast reconstruction, chemotherapy drug regimens, external and intraoperative radiation therapy, radiofrequency ablation, hormone therapy agents, and biologic therapies. The paper also addresses genetic testing for BRCA mutations, the role of psychological therapy in improving patient outcomes, and the importance of patient education and awareness in treatment decision-making.
Breast cancer is the most common cause of cancer-related deaths in females, and its rising incidence makes it the second most common cause of cancer deaths across both genders. Its incidence increases with age and with having first-degree relatives affected by the illness. However, only five to ten percent of all breast cancers are hereditary. The BRCA1, BRCA2, and p53 genes have been identified as the mutations involved. Other risk factors include prior breast cancer, a lengthy reproductive life, nulliparity, obesity, exogenous estrogen intake, and pre-existing proliferative fibrocystic changes, especially atypical hyperplasia (Abbas et al., 739–750).
Treatment efficacy depends on several factors. The type of tumor determines its aggressiveness. A well-defined tumor that is small in size, belonging to a less invasive variant, with estrogen and progesterone receptor sensitivity, generally responds well to treatment. However, tumors that are aggressive in nature, poorly defined, with axillary lymph node involvement, overexpression of c-erbB2 (HER2/neu), and evidence of S-phase and DNA ploidy abnormalities carry a poorer prognosis (Abbas et al., 739–750).
Modern technology and research have brought forward several treatment modalities with proven efficacy for patients suffering from the disease. Moreover, ongoing research and clinical trials worldwide continue to yield increasingly promising results.
Surgery is generally described as the "primary treatment for breast cancer" (Stanford Medicine: Cancer Institute), as it eliminates the tumor at its source and prevents regrowth. Pre-invasive or well-defined invasive lesions usually require only a lumpectomy, which excises the lump along with a margin of normal tissue. This is typically accompanied by radiation therapy to ensure the destruction of any microscopic deposits of cancer cells elsewhere in the breast, while the remaining breast tissue is left intact (Stanford Medicine: Cancer Institute).
If the growing tumor is less well defined, a simple or modified mastectomy may be performed. In a simple mastectomy (also known as a total mastectomy), the entire breast tissue is removed along with some axillary lymph nodes. The skin of the breast can safely be left intact — a procedure known as skin-sparing mastectomy — if the tumor is not close to the surface. Nipple-areolar-sparing mastectomy is a newer approach that preserves the breast skin along with the nipple-areolar complex, though the long-term safety of this approach has not yet been clearly established (Stanford Medicine: Cancer Institute).
Modified radical mastectomy involves removal of the entire breast along with the overlying skin, the nipple-areolar complex, the axillary lymph nodes, and the lining over the chest muscles. Radical mastectomy, the most extensive form, removes all of the above as well as the chest muscles themselves. These two forms of surgery are performed when the tumor has aggressively spread to the axillary lymph nodes and chest muscles, which may occur in cases where the cancer was not diagnosed early (Stanford Medicine: Cancer Institute).
However challenging a mastectomy may be for a patient, it is a curative modality that provides the surgeon with confidence that the tumor has been completely removed. When a radical or modified radical mastectomy is necessary, it can be accompanied by breast reconstruction surgery to restore symmetry or approximate a natural appearance, particularly in cases where both breasts are removed (Stanford Medicine: Cancer Institute). Reconstruction may be performed immediately at the time of mastectomy or delayed to a subsequent surgery. It can be carried out using implants or autologous tissue. When implants are used, silicone expanders are placed between the skin and chest wall to allow the soft tissues of the breast to expand gradually; once the desired volume is achieved, the expanders are replaced with permanent implants. Alternatively, the transverse rectus abdominis muscle from the patient's own abdomen can be harvested and placed in the mastectomy wound to reconstruct the breast mound (Stanford Medicine: Cancer Institute).
Chemotherapy is another major treatment option. It can be administered before surgery to conserve as much of the breast as possible, or after surgery in cases of aggressive tumors. Chemotherapy refers to anti-cancer drug therapy designed to kill rapidly dividing cells. Because other rapidly dividing cells — such as those in the gastrointestinal tract and the skin — are also affected, unwanted side effects are common. The side effects vary by drug and by individual and may be mild, moderate, or severe depending on the drug combination, dose, and duration of therapy (Harvey and Champe).
A number of different drug combinations are used for breast cancer, including: Adriamycin and Cytoxan; Adriamycin and Taxotere; Cytoxan, methotrexate, and fluorouracil; and fluorouracil, Adriamycin, and Cytoxan, each used at varying doses and frequencies. The type of cancer, menopausal status, and other comorbid conditions determine which chemotherapy regimen is most appropriate (Harvey and Champe).
Radiation therapy is another key option. The conventional form is external beam therapy, which is typically delivered over three to six weeks. Radiation is targeted directly at the cancer cells, with or without inclusion of the axillary lymph nodes. Advances in this modality include intraoperative radiation therapy (IORT) and 3D conformal accelerated partial breast irradiation (APBI), both of which allow a single dose of radiation to be delivered during tumor surgery. In IORT, radiation is delivered through the surgical incision, targeting the breast tissue directly. 3D conformal APBI further limits radiation to only the portion of the breast from which the tumor was removed, rather than the entire breast (Stanford Medicine: Cancer Institute).
Radiofrequency ablation is a method that uses electrical current to destroy cancer cells. Widely used for liver cancers, it is now being studied for breast cancer treatment. At the Anderson Cancer Center, clinical trials are planned to evaluate the efficacy of ablating breast tumors in combination with radiation, without the need for surgery (Sabel).
"Estrogen blockers, aromatase inhibitors, and immune agents"
"BRCA testing, psychological therapy, and patient outcomes"
"Patient education, shared decision-making, and advocacy"
Always verify citation format against your institution’s current style guide requirements.